Author: biocytogen

Beijing Biocytogen Company Name Change Annuncement

January 15, 2021

Effective December 29th, 2020, our parent company name has officially changed from Beijing Biocytogen Co., Ltd. to Biocytogen Pharmaceuticals (Beijing) Co., Ltd. There is no change in company ownership, operations, or pre-existing contractual agreements. Please feel free to contact us at [email protected] if you have any inquiries. We thank you for your continued support.

Read More

Biocytogen Enters into RenMab™/RenLite™ Licensing Agreement with Xencor

December 7, 2020

Xencor to use RenLite™ Fully Human Antibody Mouse Platform to discover novel antibody drugs WAKEFIELD, Mass. and BEIJING, Dec. 7, 2020 /PRNewswire/–Beijing Biocytogen Co., Ltd. , Biocytogen Boston Corp (collectively as “Biocytogen”) announced today that they have reached an agreement with Xencor, Inc., for the licensing of Biocytogen’s fully human antibody RenMab™/RenLite™ Mouse platform to enhance Xencor’s monoclonal […]

Read More

Biocytogen Teams With Ina Research To Boost Presence In Japan

December 4, 2020

Beijing, China and Nagano, Japan; November 30, 2020-Beijing Biocytogen Co., Ltd. (hereinafter “Biocytogen”) announced today that it has entered into a commercial agency agreement with Ina Research Co., Ltd. (hereinafter “INA”) to expand its business in Japan market. As one of the world’s largest pharmaceutical markets, Japan has an established reputation for innovative drug research […]

Read More

Antibody Engineering & Therapeutics Virtual 2020

December 2, 2020

Agenda  Book Now Presentation: Advancing Therapeutic Antibody discovery using RenMab/RenLite/RenMab KO immunoglobulin humanized mouse platforms Speaker: Li Hui, PhD, MD, Scientific Director of Biocytogen Boston Corp. Time: 9:30am – 10:00am EST December 16th To human or to humanize? This is a great question for therapeutic antibody discovery. Human antibodies that are generated from immunoglobulin transgenic mice […]

Read More

Festival of Biologics Basel 2020

November 2, 2020

Therapeutic Antibody Hit Generation Using Fully Human Antibody Transgenic Mice RenMab™ and RenLite™ Speaker: Qingcong Lin, CEO of Biocytogen Boston Corp Time: 1:30pm GMT/8:30am ET, November 5th Rapidly therapeutic antibody candidate generation using fully human antibody transgenic mouse RenMab Bispecific antibody hit and candidate generation using common light chain transgenic mouse RenLite Novel antibody hit […]

Read More

Celebrating World CRISPR Day

October 29, 2020

Please fill out the form on the left side to consult with our gene editing specialist. To learn more, download gene editing services brochure.

Read More

Immuno-Oncology Summit Virtual Summit 2020

October 1, 2020

About the Immuno-Oncology Summit Over the past 8 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline. Every year, we assemble an international mix of thought leaders and decision makers from industry and academia to […]

Read More

Emerging biotechnology company Biocytogen raised 142 million dollars (USD) in support of Project Integrum

September 24, 2020

BEIJING and BOSTON, Sept. 24, 2020 /PRNewswire/ — In August, Beijing Biocytogen Biotechnology Co., Ltd. (“Biocytogen”) announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully raising 142 million dollars (USD) meant to further secure the implementation of Project Integrum. Project Integrum is a […]

Read More

Strategic collaboration agreement reached between Biocytogen and Berkeley Lights for second Beacon Optofluidic system

September 18, 2020

September 14, 2020, Beijing | Beijing Biocytogen Co., Ltd. (“Biocytogen”) reached a collaboration with Berkeley Lights Inc. (“Berkeley Lights”) on the introduction of the second Beacon Optofluidic system. The system will be used in the development of antibody therapeutics to further strengthen the overall drug discovery capabilities of Biocytogen. The two parties will draw on […]

Read More

PEGS Boston Virtual Summit

August 20, 2020

Presentation Title: Accelerating Therapeutic Antibody Discovery with Three Distinct Humanized Mouse Models Time: 9:45 AM – 10:10 AM EDT on Monday, August 31 Programs: Antibody for Cancer Therapy  Speaker: Qingcong Lin, PhD, CEO, Biocytogen Boston Corp. With a robust immune response, RenMab™ Mouse produces fully-human antibodies with high specificity and diverse epitope coverage. To identify […]

Read More

Back to top